The Drug Enforcement Administration (DEA) recently postponed its decision on reclassifying marijuana under federal law, with a hearing set for December 2, 2024. This delay means that any final decision on marijuana rescheduling won’t be made until after the November presidential election, potentially delaying until 2025. The rescheduling, proposed by the Biden administration, follows an October 2022 cannabis policy review ordered by President Biden, which also led to the pardon of individuals convicted for simple cannabis possession.

The Push for Marijuana Rescheduling

In January 2024, the Department of Health and Human Services (HHS) reviewed the available scientific evidence and found marijuana fit the criteria for reclassification under the Controlled Substances Act (CSA). This move was seen as a step toward recognizing the medical benefits of cannabis, with support from the U.S. Food and Drug Administration (FDA), which highlighted its legitimate medical uses. Following this, the DEA issued a proposed rule to reschedule marijuana, opening a public comment period that allowed Americans to express their opinions on the matter.

Public Comments in Favor of Reform

Cannabis data firm Headset analyzed the public comments submitted during the comment period and found that 92.45% of respondents supported rescheduling marijuana, while only 7.55% opposed it. Interestingly, a large portion of those in favor, nearly 62%, advocated for full descheduling, which would remove cannabis from federal drug control laws entirely, while 38% supported moving it to a less restrictive category than Schedule III. This overwhelming support from the public highlights the desire for reform in cannabis policy.

Industry Reaction to the Delay

The cannabis industry has expressed frustration with the DEA’s decision to delay the rescheduling process. If cannabis were reclassified to Schedule III, it would significantly impact the financial landscape for cannabis businesses. Under current regulations, cannabis companies are subject to Section 280E of the Internal Revenue Code, which prohibits them from taking standard tax deductions. Reclassification would ease this burden, improving profitability for businesses struggling under the current tax regime.

Lauren Fontein, chief compliance officer and founder of The Artist Tree, expressed disappointment, stating, "It means that cannabis businesses may be subject to one additional year of taxation under 280E, which makes a tremendous difference to the bottom line for cannabis companies." George Sadler, CEO and co-founder of Gelato Canna Co., echoed this sentiment, accusing the government of delaying meaningful reform. "The people have spoken. They want cannabis legalized. This is more of the same: delay, over regulate, over tax," he said.

Why the Delay?

Several factors contribute to the delay in marijuana rescheduling. The DEA and HHS must conduct thorough reviews of the scientific evidence regarding marijuana’s medical use, safety, and potential for abuse. The public comment period also allows for the input of various stakeholders, including healthcare providers, cannabis businesses, and advocates. Additionally, political considerations play a role, with some speculating that the decision may have been postponed to avoid influencing the upcoming presidential election.

Ian Rice, CEO of cannabis consulting firm Envirocann, remarked on the complexity of federal cannabis reform. "The DEA’s decision to hold a hearing on rescheduling cannabis to Schedule III demonstrates the complexity and ongoing challenges of federal cannabis reform," he said. Elmar Mair, CEO of Neatleaf, emphasized the societal impact of the delay, noting that rescheduling could help address legal and criminal justice issues related to cannabis, such as releasing those wrongfully imprisoned for marijuana-related offenses.

The Path Forward

While the DEA’s delay is a setback for those hoping for immediate reform, the rescheduling process continues to move forward. The December hearing will be an opportunity for further examination of the scientific and legal aspects of cannabis rescheduling, and public opinion remains overwhelmingly in favor of reform. Advocates continue to push for broader legalization efforts through state legislatures and ballot initiatives, hoping to achieve a more comprehensive overhaul of cannabis laws.

As the industry awaits the DEA’s final decision, the implications of rescheduling remain significant, from tax relief for businesses to potential changes in medical cannabis policy. The outcome of this process will undoubtedly shape the future of cannabis in the United States, and stakeholders are watching closely to see how the landscape will evolve post-election.

In summary, the DEA’s delay in rescheduling marijuana reflects the intricate interplay of scientific review, public feedback, and political considerations. With the hearing scheduled for December 2024, cannabis reform advocates and businesses must wait a bit longer to see whether the federal government will take this critical step toward recognizing the medical benefits of cannabis.